1468 related articles for article (PubMed ID: 33712270)
1. Inpatient Omission of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Is Associated With Morbidity and Mortality in Coronavirus Disease 2019.
Oddy C; Allington J; McCaul J; Keeling P; Senn D; Soni N; Morrison H; Mawella R; Samuel T; Dixon J
Clin Ther; 2021 Apr; 43(4):e97-e110. PubMed ID: 33712270
[TBL] [Abstract][Full Text] [Related]
2. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
3. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
Khera R; Clark C; Lu Y; Guo Y; Ren S; Truax B; Spatz ES; Murugiah K; Lin Z; Omer SB; Vojta D; Krumholz HM
J Am Heart Assoc; 2021 Jul; 10(13):e018086. PubMed ID: 33624516
[TBL] [Abstract][Full Text] [Related]
4. Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study.
Christiansen CF; Heide-Jørgensen U; Rasmussen TB; Bodilsen J; Søgaard OS; Maeng M; Vistisen ST; Schmidt M; Pottegård A; Lund LC; Reilev M; Hallas J; Johansen NB; Brun NC; Sørensen HT; Thomsen RW
J Am Heart Assoc; 2020 Oct; 9(19):e017297. PubMed ID: 32998607
[TBL] [Abstract][Full Text] [Related]
5. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
[TBL] [Abstract][Full Text] [Related]
6. ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19.
Tetlow S; Segiet-Swiecicka A; O'Sullivan R; O'Halloran S; Kalb K; Brathwaite-Shirley C; Alger L; Ankuli A; Baig MS; Catmur F; Chan T; Dudley D; Fisher J; Iqbal MU; Puczynska J; Wilkins R; Bygate R; Roberts P
J Intern Med; 2021 May; 289(5):688-699. PubMed ID: 33210357
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
8. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.
Hippisley-Cox J; Young D; Coupland C; Channon KM; Tan PS; Harrison DA; Rowan K; Aveyard P; Pavord ID; Watkinson PJ
Heart; 2020 Oct; 106(19):1503-1511. PubMed ID: 32737124
[TBL] [Abstract][Full Text] [Related]
9. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
Li EC; Heran BS; Wright JM
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
[TBL] [Abstract][Full Text] [Related]
11. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
12. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
Hakeam HA; Alsemari M; Duhailib ZA; Ghonem L; Alharbi SA; Almutairy E; Sheraim NMB; Alsalhi M; Alhijji A; AlQahtani S; Khalid M; Barry M
J Cardiovasc Pharmacol Ther; 2021 May; 26(3):244-252. PubMed ID: 33231487
[TBL] [Abstract][Full Text] [Related]
13. Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.
Chan CK; Huang YS; Liao HW; Tsai IJ; Sun CY; Pan HC; Chueh JS; Wang JT; Wu VC; Chu TS;
Hypertension; 2020 Nov; 76(5):1563-1571. PubMed ID: 32869673
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
Haroon S; Subramanian A; Cooper J; Anand A; Gokhale K; Byne N; Dhalla S; Acosta-Mena D; Taverner T; Okoth K; Wang J; Chandan JS; Sainsbury C; Zemedikun DT; Thomas GN; Parekh D; Marshall T; Sapey E; Adderley NJ; Nirantharakumar K
BMC Infect Dis; 2021 Mar; 21(1):262. PubMed ID: 33722197
[TBL] [Abstract][Full Text] [Related]
15. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
[TBL] [Abstract][Full Text] [Related]
16. The concern about ACE/ARB and COVID-19: Time to hold your horses!
Pergolizzi JV; Varrassi G; Magnusson P; LeQuang JA; Leopoulou M; Paladini A; Taylor R; Wollmuth C; Breve F;
J Am Pharm Assoc (2003); 2020; 60(6):e88-e90. PubMed ID: 32747165
[TBL] [Abstract][Full Text] [Related]
17. Increased Incidence, Morbidity, and Mortality in Human Coronavirus NL63 Associated with ACE Inhibitor Therapy and Implication in SARS-CoV-2 (COVID-19).
Krvavac A; Patel TP; Karle EM; Epstein NB; Reznikov EA; Gates LG; Holliday ZM
Mo Med; 2020; 117(4):346-354. PubMed ID: 32848272
[TBL] [Abstract][Full Text] [Related]
18. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
[TBL] [Abstract][Full Text] [Related]
19. Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people.
Dambha-Miller H; Hinton W; Wilcox CR; Lemanska A; Joy M; Feher M; Stuart B; de Lusignan S; Hippisley-Cox J; Griffin S
Fam Pract; 2023 Mar; 40(2):330-337. PubMed ID: 36003039
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
Kim JH; Baek YH; Lee H; Choe YJ; Shin HJ; Shin JY
Epidemiol Health; 2021; 43():e2021004. PubMed ID: 33445824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
